Literature DB >> 22733264

Diabetes: choosing a second-line therapy after metformin in type 2 diabetes mellitus.

Carol Wilson.   

Abstract

Entities:  

Year:  2012        PMID： 22733264     DOI： 10.1038/nrendo.2012.107

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  2 in total

1.  Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.

Authors:  Pablo Aschner; Juliana Chan; David R Owens; Sylvie Picard; Edward Wang; Marie-Paule Dain; Valérie Pilorget; Akram Echtay; Vivian Fonseca
Journal:  Lancet       Date:  2012-06-09       Impact factor: 79.321

2.  Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.

Authors:  Baptist Gallwitz; Juan Guzman; Francesco Dotta; Bruno Guerci; Rafael Simó; Bruce R Basson; Andreas Festa; Jacek Kiljański; Hélène Sapin; Michael Trautmann; Guntram Schernthaner
Journal:  Lancet       Date:  2012-06-09       Impact factor: 79.321
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.